SAREPTA THERAPEUTICS INC (SRPT)
US8036071004 - Common Stock
We assign a fundamental rating of 5 out of 10 to SRPT. SRPT was compared to 565 industry peers in the Biotechnology industry. SRPT has an average financial health and profitability rating. SRPT is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
SRPT had positive earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
SRPT had negative earnings in each of the past 5 years.
In the past 5 years SRPT reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of SRPT (3.38%) is better than 93.76% of its industry peers.
SRPT's Return On Equity of 9.98% is amongst the best of the industry. SRPT outperforms 95.54% of its industry peers.
SRPT has a Return On Invested Capital of 2.21%. This is amongst the best in the industry. SRPT outperforms 93.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.38% | ||
| ROE | 9.98% | ||
| ROIC | 2.21% |
ROA(3y)-17.4%
ROA(5y)-22%
ROE(3y)-96.74%
ROE(5y)-90.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRPT has a better Profit Margin (7.43%) than 94.30% of its industry peers.
SRPT's Operating Margin of 4.94% is amongst the best of the industry. SRPT outperforms 93.94% of its industry peers.
SRPT has a Gross Margin of 85.92%. This is amongst the best in the industry. SRPT outperforms 88.95% of its industry peers.
SRPT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.94% | ||
| PM (TTM) | 7.43% | ||
| GM | 85.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SRPT is destroying value.
SRPT has more shares outstanding than it did 1 year ago.
SRPT has more shares outstanding than it did 5 years ago.
SRPT has a better debt/assets ratio than last year.
2.2 Solvency
SRPT has an Altman-Z score of 2.15. This is not the best score and indicates that SRPT is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of SRPT (2.15) is better than 72.73% of its industry peers.
A Debt/Equity ratio of 0.93 indicates that SRPT is somewhat dependend on debt financing.
SRPT has a Debt to Equity ratio of 0.93. This is in the lower half of the industry: SRPT underperforms 78.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.15 |
ROIC/WACC0.22
WACC9.86%
2.3 Liquidity
SRPT has a Current Ratio of 3.84. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
SRPT has a Current ratio (3.84) which is comparable to the rest of the industry.
SRPT has a Quick Ratio of 3.03. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SRPT (3.03) is worse than 61.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.03 |
3. Growth
3.1 Past
SRPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 115.96%, which is quite impressive.
The Revenue has grown by 48.46% in the past year. This is a very strong growth!
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.80% yearly.
EPS 1Y (TTM)115.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.91%
Revenue 1Y (TTM)48.46%
Revenue growth 3Y32.04%
Revenue growth 5Y32.8%
Sales Q2Q%40.79%
3.2 Future
The Earnings Per Share is expected to grow by 33.66% on average over the next years. This is a very strong growth
SRPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.08% yearly.
EPS Next Y130.76%
EPS Next 2Y97.78%
EPS Next 3Y62.76%
EPS Next 5Y33.66%
Revenue Next Year45.2%
Revenue Next 2Y60.82%
Revenue Next 3Y45.19%
Revenue Next 5Y26.08%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
SRPT is valuated quite expensively with a Price/Earnings ratio of 88.40.
Based on the Price/Earnings ratio, SRPT is valued cheaply inside the industry as 93.58% of the companies are valued more expensively.
SRPT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.96.
With a Price/Forward Earnings ratio of 9.44, the valuation of SRPT can be described as very reasonable.
Based on the Price/Forward Earnings ratio, SRPT is valued cheaper than 97.86% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.82. SRPT is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 88.4 | ||
| Fwd PE | 9.44 |
4.2 Price Multiples
93.76% of the companies in the same industry are more expensive than SRPT, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 80.07 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SRPT's earnings are expected to grow with 62.76% in the coming years.
PEG (NY)0.68
PEG (5Y)N/A
EPS Next 2Y97.78%
EPS Next 3Y62.76%
5. Dividend
5.1 Amount
SRPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SAREPTA THERAPEUTICS INC
NASDAQ:SRPT (11/21/2024, 8:00:01 PM)
After market: 110.98 +0.48 (+0.43%)110.5
-0.36 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.55B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 88.4 | ||
| Fwd PE | 9.44 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.68
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.38% | ||
| ROE | 9.98% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 4.94% | ||
| PM (TTM) | 7.43% | ||
| GM | 85.92% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.03 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)115.96%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y130.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)48.46%
Revenue growth 3Y32.04%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y